MaxCyte Q4 2025 revenue fell 16% to USD 7.3 million as net loss narrowed to USD 10 million

Reuters
Mar 25
MaxCyte Q4 2025 revenue fell 16% to USD 7.3 million as net loss narrowed to USD 10 million
  • MaxCyte published a quarterly and annual earnings press release reporting Q4 total revenue of USD 7.3 million, down 16%.
  • Core business revenue in Q4 was USD 6.8 million, down 22%, while SPL program-related revenue was USD 0.5 million.
  • FY total revenue was USD 33.0 million, down 15%, and management said results were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from its largest customer.
  • Net loss was USD 9.6 million in Q4 and USD 44.6 million in FY.
  • 2026 revenue guidance was USD 30.0-32.0 million, including core revenue of USD 25.0-27.0 million and about USD 5.0 million of SPL program-related revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603241605PRIMZONEFULLFEED9677856) on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10